Sylvia Mcbrinn

Sylvia Mcbrinn

Direktor/Vorstandsmitglied bei BIOATLA, INC.

Vermögen: 53 794 $ am 31.05.2024

71 Jahre
Health Technology
Consumer Services
Technology Services

Profil

Propel Bio Partners Senior Advisor Sylvia McBrinn is also a strategic Board Director, CEO, and commercialization expert with 30+ years of leadership experience in the biopharmaceutical industry.
With a strong commercial background in US and global markets, she has led successful launches of specialty to blockbuster products and grown market share for companies including Pfizer and Vernalis.
She provides biopharmaceutical companies critical insights from a career of executive governance, operational, and commercial success across a wide range of therapeutic areas including neurology, inflammation and rheumatology, pain, infectious disease/microbiome, and urology.
Currently, she serves and advises BioAtla (Nasdaq: BCAB) as Board Director, Compensation Committee Chair, and Audit Committee member, and as a Board Director of Ilya Pharma (private).
Until recently, she led as Board Director/founding CEO of early-stage biotech company Axerion Therapeutics (now ReNetX Bio), and also built and led the US subsidiary of a British biotech, Vernalis, with full P&L oversight.
Earlier, she was an EVP and GM of Andrx with full P&L responsibility, overseeing branded products with 400 employees across key business functions.
Throughout her career and board roles, she has earned a reputation of a strategic thinker with the ability to connect the dots and ask insightful questions between business direction, portfolio strategy, R&D, marketing, and commercialization.
As Global VP of Marketing at Pfizer, Ms. McBrinn led the launch and commercialization of the blockbuster product Bextra—the #1 Product launch in the US that year—achieving $1B in sales in the first 12 months and exceeding forecast by 35%.
Additionally, she built the #1 Parkinson’s disease product franchise globally, exceeding forecast by 40%.
At Vernalis, she in-licensed and relaunched Apokyn, an injectable Parkinson’s product that increased sales 42% YOY.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
13.06.2024 35 625 ( 0,07% ) 53 794 $ 31.05.2024

Aktive Positionen von Sylvia Mcbrinn

UnternehmenPositionBeginn
BIOATLA, INC. Direktor/Vorstandsmitglied 15.06.2021
Corporate Officer/Principal 01.01.2014
Berater 01.03.2022
Alle aktiven Positionen von Sylvia Mcbrinn

Ehemalige bekannte Positionen von Sylvia Mcbrinn

UnternehmenPositionEnde
Direktor/Vorstandsmitglied 01.06.2023
Gründer 01.01.2012
Vernalis Pharmaceuticals, Inc. Corporate Officer/Principal 01.12.2008
Corporate Officer/Principal 01.01.2004
Corporate Officer/Principal 01.01.2003
Sehen Sie sich die Erfahrung von Sylvia Mcbrinn im Detail an

Ausbildung von Sylvia Mcbrinn

DeSales University Undergraduate Degree
Widener University Masters Business Admin

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Sylvia Mcbrinn im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

14

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen2
PFIZER, INC.

Health Technology

BIOATLA, INC.

Health Technology

Private Unternehmen10
Pharmacia & Upjohn, Inc.

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Technology Services

Health Technology

Vernalis Pharmaceuticals, Inc.

Health Technology

Finance

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Sylvia Mcbrinn